Akero Therapeutics’ Post

📢 Exciting News in the Field of Gastroenterology! 🌟 SS Pharma is thrilled to share that the University of Birmingham is conducting a groundbreaking clinical trial named FARGO. This trial aims to explore whether faecal microbiota transplantation can effectively correct gut microbiome imbalances in patients with primary sclerosing cholangitis (PSC). Primary sclerosing cholangitis is a chronic liver disease that significantly impacts patients' quality of life. By addressing gut microbiome imbalances, the FARGO trial holds the potential to offer new hope and improved outcomes for PSC patients. We eagerly anticipate the results and the positive impact this trial could have on the PSC community. Stay tuned for updates! #ClinicalTrials #PSC #GutHealth #Microbiome #MedicalResearch #SSPharma #HealthcareInnovation

2,237 Patients, 11 Hospitals, four HCC Criteria: A Comparison Study A recent study, conducted across 11 South Korean hospitals, compared the diagnostic performance of four hepatocellular carcinoma (HCC) diagnostic guidelines and readers' judgments. The study by Jeong Min Lee and colleagues was retrospective, involving 2,237 patients at risk for HCC with 2,445 focal liver lesions (FLLs). FLLs were reviewed according to four guidelines: AASLD/LI-RADS, KLCA-NCC, EASL, and APASL, assessed on accuracy, sensitivity, specificity, positive predictive value, and negative predictive value. Read more about the study here: https://bit.ly/4eFNfp5 Get updates on expert insights and the latest studies using #mintLesion™ to transform medical research by following #ResearchWithMint. #ClinicalResearch

🔈 BIG NEWS! DECISION has enrolled the first patient at Hôpital Beaujon, Clichy, France in the COMBAT Trial, a multicenter, randomized, open-label, Phase II clinical trial. This trial is a crucial component of the DECISION project, which aims to transform the treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF), investigating albumin and enoxaparin, a potential combinatorial therapy for decompensated cirrhosis. Read more in our press release: https://lnkd.in/dcsrwc54 Pierre-Emmanuel Rautou Greater Paris University Hospitals - AP-HP CARACENI Paolo Alma Mater Studiorum – Università di Bologna European Foundation for the Study of Chronic Liver Failure (EF CLIF) EASL | The Home of Hepatology #COMBATtrial #hepatology #cirrhosis #decompensation #ACLF #liver #Albumin #Enoxaparin #ClinicalTrial #PhaseIItrial #SciComm 

Dr. Michael Weinstein of Capital Digestive Care interviews Dr. Andreas Muehler, chief medical officer of Immunic Therapeutics, which is developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Join Dr. Weinstein and Dr. Muehler as they explore the challenges faced by patients with #celiacdisease and new innovations that will impact the way physicians treat their patients. #independentGI #gastroenterology #endoscopy

Use of the a liquid NIT can significantly reduce unnecessary biopsies in screening for MASH clinical trials. In an article from Journal of Hepatology a retrospective simulation analysis of a 1,929-patient cohort revealed that the NIS2+(TM) test reduced the liver biopsy failure rate to 39%, compared to FIB-4 (58%) or the screening pathway used originally with this cohort (60%). This led to dramatic and significant reductions in unnecessary liver biopsies in patients who NIS2+ would have screened out correctly as well as screening costs. More Info: https://hubs.la/Q02yGx0P0 #NIS2 #NonInvasiveLiverTest

Our following case report illustrates the multiple diagnostic and treatment challenges arising from immunotherapy with pembrolizumab 😃

Don't overlook the chance to get your research published in the Global Journal of Gastroenterology & Hepatology Research. Please submit your manuscripts. To know more, visit here: https://lnkd.in/dqiVVkeZ WhatsApp Us: +447723493307 #GICancerResearch #GIcancer #GastroCancer #ColonCancer #RectalCancer #EsophagealCancer #StomachCancer #LiverCancer #PancreaticCancer #EsophagealDisease #GastricDisease #EsophagealHealth #GastricHealth #EsophagealDisorders

A recent study presented in EASL aims to to assess retrospectively, LIVERSTAT performance and concordance rate (CR) with liver biopsy and Fibroscan as second step after FIB-4 for the assessment of advanced fibrosis (F3F4) in NAFLD patients. 176 NAFLD Patients with prospectively collected LIVERSTAT have been included from a tertiary hepatology center with biopsy- proven NAFLD and concomitant FIB-4 and liver stiffness measurement (LSM). AUC(SE) and C-statistics were used to assess the accuracy of each noninvasive test (NIT) against liver biopsy. Conclusion is that (LIVERSTAT), is readily available and can be used to identify F3-F4 as a second step in patients with indeterminate FIB-4. Find out more about the study: https://lnkd.in/gydCyJ2Y   #liverstats #liverscreening #fibrostudies

- Observational data from population-based studies show that GLDs like SGLT2is are linked to better long-term liver outcomes in T2D patients with NAFLD. - SGLT2is were associated with the strongest reduction in NAFLD incidence, cirrhosis, and composite liver-related events compared to other medications. - TZDs were associated with a reduced risk of developing NAFLD and cirrhosis but were not significantly associated with a lower incidence of hepatocellular carcinoma. - GLP-1 RAs demonstrated a significant association with reduced liver-related mortality. Our latest published meta-analysis in Diabetic Medicine. https://lnkd.in/gewkV4MC

I'm happy to share that our paper, "Diagnostic and Prognostic Value of Machine Perfusion Biomarkers in Kidney Graft Evaluation," has been published in Transplantation Proceedings. This review investigates the innovative use of machine perfusion biomarkers to enhance the evaluation of kidney grafts, potentially revolutionizing transplantation outcomes. I want to thank collaborators, Divya Srinivasan and Dominik Todorov for their dedication and hard work. A special thanks to Professor Dr Vassilios Papalois for his supervision and guidance throughout this journey. You can find our narrative review here: https://lnkd.in/dHxupw6A #Transplantation #KidneyResearch #MedicalInnovation #noninvasivegraftevaluation #biomarkers